Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Cancer immunotherapies, such as atezolizumab, are proving to be a valuable therapeutic strategy across indications, including non–small cell lung cancer (NSCLC) and urothelial cancer (UC). Here, we describe a diagnostic assay that measures programmed-death ligand 1 (PD-L1) expression, via immunohist...

Descripción completa

Detalles Bibliográficos
Autores principales: Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369970/
https://www.ncbi.nlm.nih.gov/pubmed/29346180
http://dx.doi.org/10.1097/PAI.0000000000000594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369970/
https://www.ncbi.nlm.nih.gov/pubmed/29346180
http://dx.doi.org/10.1097/PAI.0000000000000594

Ejemplares similares